Cargando…

Correction to: Functional Relevance of CTLA4 Variants: an Upgraded Approach to Assess CTLA4‑Dependent Transendocytosis by Flow Cytometry

Detalles Bibliográficos
Autores principales:	Rojas‑Restrepo, Jessica, Sindram, Elena, Zenke, Simon, Haberstroh, Hanna, Mitsuiki, Noriko, Gabrysch, Annemarie, Huebscher, Katrin, Posadas‑Cantera, Sara, Krausz, Máté, Kobbe, Robin, Rohr, Jan C., Grimbacher, Bodo, Gamez‑Diaz, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661779/ https://www.ncbi.nlm.nih.gov/pubmed/37812314 http://dx.doi.org/10.1007/s10875-023-01596-3

Ejemplares similares

Functional Relevance of CTLA4 Variants: an Upgraded Approach to Assess CTLA4-Dependent Transendocytosis by Flow Cytometry
por: Rojas-Restrepo, Jessica, et al.
Publicado: (2023)

Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency?
por: Krausz, Máté, et al.
Publicado: (2022)

Corrigendum: Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency?
por: Krausz, Máté, et al.
Publicado: (2023)

Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis
por: Williams, Cayman, et al.
Publicado: (2022)

The ABACHAI clinical trial protocol: Safety and efficacy of abatacept (s.c.) in patients with CTLA-4 insufficiency or LRBA deficiency: A non controlled phase 2 clinical trial
por: Krausz, Máté, et al.
Publicado: (2022)

Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation
por: Kennedy, Alan, et al.
Publicado: (2022)

Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers
por: Egg, David, et al.
Publicado: (2018)

The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80
por: Kennedy, Alan, et al.
Publicado: (2023)

Establishing the Molecular Diagnoses in a Cohort of 291 Patients With Predominantly Antibody Deficiency by Targeted Next-Generation Sequencing: Experience From a Monocentric Study
por: Rojas-Restrepo, Jessica, et al.
Publicado: (2021)

Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms
por: Berry, Andrew, et al.
Publicado: (2008)

CTLA-4: From conflict to clinic
por: Bashyam, Hema
Publicado: (2007)

The role of CTLA-4 in immune regulation
por: Verhagen, Johan, et al.
Publicado: (2008)

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
por: Watanabe, Tomofumi, et al.
Publicado: (2023)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

CTLA-4 Insufficiency due to a Novel CTLA-4 Deletion, Identified through Copy Number Variation Analysis
por: Olfe, Lisa, et al.
Publicado: (2022)

Autosomal-dominant immune dysregulation syndrome in humans with CTLA4 mutations
por: Schubert, Desirée, et al.
Publicado: (2014)

CTLA4 polymorphism and primary Sjögren's syndrome
por: Lester, Susan, et al.
Publicado: (2007)

CTLA-4 based therapy (MDX-010)
por: Korman, A
Publicado: (2003)

CTLA-4 and Autoimmunity: New Twists in the Tale
por: Walker, Lucy S.K.
Publicado: (2015)

Effects of CTLA4-Ig on human monocytes
por: Tono, Toshihiro, et al.
Publicado: (2017)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma
por: Hoffmann, Friederike, et al.
Publicado: (2023)

(64)Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues
por: Higashikawa, Kei, et al.
Publicado: (2014)

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
por: Du, Xuexiang, et al.
Publicado: (2018)

TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
por: Khanolkar, Rahul C., et al.
Publicado: (2022)

CTLA-4 CT-60 A/G and CTLA-4 1822 C/T Gene Polymorphisms in Indonesians with Type 1 Diabetes Mellitus
por: Rochmah, Nur, et al.
Publicado: (2022)

CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells
por: Gaber, Timo, et al.
Publicado: (2018)

Blood PD-1(+)TFh and CTLA-4(+)CD4(+) T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis
por: Aldridge, Jonathan, et al.
Publicado: (2021)

CTLA-4: a negative regulator of autoimmune disease
Publicado: (1996)

CTLA-4 blockade: therapeutic potential in cancer treatments
por: Tarhini, Ahmad A, et al.
Publicado: (2010)

Comparison of the Intracellular Trafficking Itinerary of CTLA-4 Orthologues
por: Kaur, Satdip, et al.
Publicado: (2013)

Confusing signals: Recent progress in CTLA-4 biology
por: Walker, Lucy S.K., et al.
Publicado: (2015)

CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis
por: Gerdes, Lisa Ann, et al.
Publicado: (2016)

Screening and antitumor effect of an anti-CTLA-4 nanobody
por: Wan, Ruirong, et al.
Publicado: (2018)

Two neurologic facets of CTLA4-related haploinsufficiency
por: Ayrignac, Xavier, et al.
Publicado: (2020)

CTLA-4 correlates with immune and clinical characteristics of glioma
por: Liu, Fangkun, et al.
Publicado: (2020)

Regulation of CTLA‐4 recycling by LRBA and Rab11
por: Janman, Daniel, et al.
Publicado: (2021)

A case of autoimmune enteropathy with CTLA4 haploinsufficiency
por: Miyazaki, Haruka, et al.
Publicado: (2022)

Identification of CTLA-4-Positive Cells in the Human Tonsil
por: Tiemann, Markus, et al.
Publicado: (2021)

CTLA4 prohibits T cells from cross-dressing
por: Paillon, Noémie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hpqagap36lgo2ghno5f7i0h7kh